Loading
JDQ443 is an experimental small-molecule drug from Novartis Pharmaceuticals in phase 3 trials for non-small-cell lung cancer and colorectal cancer, aimed at KRAS.
JDQ443 is a small-molecule drug developed by Novartis Pharmaceuticals. Its target is KRAS (the sponsor names KRAS G12C). ClinicalTrials.gov describes the intervention as: JDQ443 per os (PO) 200 mg twice a day continuously. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT05132075 (Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer), in non-small-cell lung cancer and colorectal cancer. The largest, NCT04699188, plans to enrol 344 participants (actual) with primary completion expected 2027-01-25. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Small-molecule drug directed at KRAS, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated. Connects to KRAS.
1.JDQ443 slips into a pocket on KRAS.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"JDQ443" OR ABSTRACT:"JDQ443") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about JDQ443, not a curated reading list.
Shares Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other, Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation, Novartis, Non-small-cell lung cancer and the tag pipeline.
Shares KRAS, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares KRAS, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Novartis, Non-small-cell lung cancer and the tag pipeline.
Shares Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Novartis, Non-small-cell lung cancer and the tag pipeline.
Shares Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.